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The effects of portal venous inoculation with donor splenocytes on lung 
allograft survival were evaluated in dogs. Within the dose range examined, 
portal venous inoculation with donor splenocytes alone did not affect the 
graft s'arvival time. Although the mean graft survival time was prolonged by 
FK 506 treatment for 14 days, the transplanted lungs were rejected within 
12 days after termination of FK 506 administration. However, when the 
recipients were given portal venous inoculation with donor splenocytes at 
the time of transplantation, the graft survival time after termination of FK 
506 administration was significantly prolongated. In the recipients that 
received combined therapy of portal venous inoculation with donor spleno- 
cytes and FK 506 treatment, arterial oxygen tension and histologic archi- 
tecture of the transplanted lungs remained within the normal range for a 
longer period than these measures did in control animals that received FK 
506 treatment alone. Dose-response xperiments revealed that 1 x 10 s 
cells/recipient was most effective in causing prolonged graft survival after 
termination of FK 506 treatment. On the basis of these results, perioper- 
ative portal venous inoculation with donor splenocytes can enhance the 
immunosuppressive effect of FK 506 in the canine lung transplantation 
model. (J Thorac Cardiovasc Surg 1996;112:300-5) 
S ince lung transplantation was first attempted clinically in 1963 by Hardy and coworkers, a it has 
been widely applied for the treatment of end-stage 
lung diseases. 2'3 From the technical standpoint, 
lung transplantation has been established as a useful 
therapeutic modality. The most important problem 
yet to be solved is to control the host's immune 
responses against transplanted organs. Although 
immunosuppressants such as cyclosporine and FK 
506 are used to overcome the host's rejection reac- 
tion, side effects of these drugs are clinically a major 
drawback.4, 5 
Therefore it is necessary to develop new thera- 
peutic procedures to reduce or avoid the use of 
immunosuppressants. One such way is to induce 
immunologic tolerance against donor antigens. In 
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rodent models of heart, kidney, and liver transplan- 
tations, graft survival could be prolonged by portal 
venous inoculation with donor lymphocytes. 6-1. In 
particular, in a rat liver transplantation model, por- 
tal venous inoculation with donor splenocytes re- 
sulted in permanent graft survival, n In experimental 
models with larger and genetically heterogenous 
animals, however, the efficacy of portal venous 
inoculation with donor splenocytes on graft survival 
remains unclear except in the recent work on the 
prolonged survival of renal allografts by this treat- 
ment in dogs. 12' 13 In the present study, we examined 
the effects of portal venous inoculation with donor 
splenocytes on graft survival in a canine lung trans- 
plantation model. 
Material and methods 
Animals. Adult mongrel dogs (body weight 8.0 to 14.5 
kg) were used. The study followed the guidelines for 
animal experimentation issued by Miyazaki Medical Col- 
lege, which were based on the "Guide for the Care and 
Use of Laboratory Animals" prepared by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
Lung transplantation. All dogs were anesthetized with 
sodium pentobarbital (25 mg/kg) by intravenous injection 
after an intramuscular injection of 0.5 mg atropine sulfate. 
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Table I. Effects of portal venous inoculation with 
donor spIenocytes on graft survival in lung 
transplantation i dogs 
No. of No. of Graft survival 
cells animals time (days) Mean ++_ SD 
None 6 4, 5, 7, 8, 9, 10 7.2 +_ 2.3 
1.0 × 106 4 7, 7, 8, 8 7.5 _+ 0.6* 
1.0 × l0 w 4 7, 8, 8, 9 8.0 ± 0.8* 
1.0 × 10 l° 4 6, 6, 7, 7 6.5 _+ 0.6* 
SD, Standard deviation. 
*Not significantly different from control group given o cells. 
They were then intubated (outer diameter 8.5 mm) and 
the lungs ventilated with a tidal volume of 30 ml/kg at a 
rate of 15 breaths/rain, with 5 cm H20 positive end- 
expiratory pressure. Allotransplantation f the left lung 
was done according to the method of Veith and Rich- 
ards.24 The left lung harvested from a size-matched donor 
was perfused with 500 ml of cold (4 ° C) saline solution 
containing heparin (10 U/ml) via the pulmonary artery at 
a pressure of 40 cm H20 and was kept on ice slush until 
transplantation. Cold ischemic time was less than 30 
minutes and warm ischemic time was less than 60 minutes. 
An inflatable cuff was placed around the proximal right 
pulmonary artery of the recipient, which allowed indepen- 
dent assessment of transplanted lung functionJ 5 
Portal venous inoculation with donor splenocytes. The 
spleen was excised from the donor immediately before 
lung transplantation. The spleen was minced and pressed 
gently through a stainless steel mesh into phosphate- 
buffered saline solution. The cell suspension was centrifuged 
at 1500 rpm for 5 minutes and resuspended in NH4C1 
solution to remove red blood cells. The cells were washed 
twice and the designated number of donor splenocytes (1 × 
108 cells/ml) was infused via the superior mesenteric vein of 
the recipients 30 minutes before lung transplantationJ 2 
Immunosuppressive drug treatment. FK 506 (Fujisawa 
Pharmaceutical Co., Ltd., Osaka, Japan) was dissolved in 
saline solution and was injected intramuscularly into the 
thigh. The dose of FK 506 was 0.1 mg/kg per day and the 
period of administration was for 14 days starting from the 
day of lung transplantation (day 0). Plasma trough levels 
of FK 506 were measured by a double antibody enzyme- 
linked immunosorbent assay method. ~6 
Experimental designs. In the first experiment, hree 
groups of dogs (4 animals each) received portal injection 
with 1 × 106, 1 x 108, or 1 x 10 l° donor splenocytes 
immediately before lung transplantation. An additional 
group (6 dogs) was given no cells but received lung 
transplantation to serve as a control group. In the second 
experiment, dogs were divided into three groups (6 ani- 
mals each). The first group (FK group) was treated with 
FK 506 for 14 days after lung transplantation, the second 
group (PV group) received portal venous inoculation with 
1 × 10 ~ donor splenocytes immediately before transplan- 
tation, and the third group (PV + FK group) received 
portal venous inoculation with donor splenocytes imme- 
diately before transplantation a d then treatment with FK 
506 for 14 days. Graft survival time of each group was 
compared with that of the control group in the first 
Table I I .  Effects of combined therapy with portal 
venous inoculation with donor splenocytes and FK 
506 administration on grafted lung in dogs 
No. of Graft survival 
Group animals time (days) Mean ++_ SD 
Control 6 4, 5, 7, 8, 9, 10 7.2 -+ 2.3 
FK 6 18, 20, 21, 22, 23, 25 21.5 ± 2.4 
PV 6 4, 5, 5, 6, 7, 10 6.2 _+ 2.1 
PV + FK 6 26, 33, 34, 36, 36, 63 38.0 ± 12.8" 
Control group, which is the same as that in Table I, received no cells and 
received lung transplantation alone. FK group was treated with FK 506 
(0.1 mg/kg per day) for 14 days tarting from day of lung transplantation. 
PV group received lung transplantation preceded byportal venous inocu- 
lation with 1 × 108 donor splenocytes. PV + FK group received lung 
transplantation and perioperative portal venous inoculation with donor 
splenocytes (1 × 108 cells) and followed by FK 506 treatment for 14 days. 
SD, Standard deviation. 
*p < 0.05 versus control group, FK group, and PV group. 
experiment. In the third experiment, wo groups of ani- 
mals (4 animals each) were given 1 x 106 and 1 x 101° 
donor splenocytes immediately before lung transplanta- 
tion, and then they were treated with FK 506 for 14 days. 
Results in this group were compared with those of the FK 
group and also with results in the PV + FK group in the 
second experiment. 
Assessments of graft survival. Grafts were evaluated 
for rejection manifested by opacification of the trans- 
planted lung on chest roentgenograms. Radiologic exam- 
inations were done every 3 days, and when rejection was 
suspected the examinations were done every day. For 
histopathologic assessment of rejection, tissue specimens 
were obtained by open lung biopsy every 7 days after 
transplantation a d on the day of rejection determined by 
radiology. Radiologic opacification corresponded to grade 
3 (moderate rejection) or 4 (severe rejection) of the 
histopathologic classification of the International Society 
for Heart Transplantation. 17 
Functional tests of the transplanted lung. A right 
pulmonary artery occlusion test was done on the day of 
transplantation a d every 7 days thereafter to evaluate the 
function of the transplanted lungs. The animals were 
maintained on a respirator under general anesthesia at a 
tidal volume of 30 ml/kg, a respiratory rate of 15 breaths/ 
rain, 5 cm H20 positive end-expiratory pressure, and an 
inspired oxygen fraction of 1.0; arterial blood gas values 
were measured 10 minutes after occlusion of the right 
pulmonary artery. 
Statistical analysis. All values were expressed as mean 
plus or minus standard eviation. The paired differences 
between groups were determined by analysis of variance 
with the StatView 4.0 (Abacus Concepts, Inc., Berkeley, 
Calif.) software package. Differences were considered to 
be significant when p values were less than 0.05. 
Results 
In the first experiment,  effects of portal  venous 
inoculat ion with donor  splenocytes alone on lung 
graft survival were examined. Three groups of dogs 
(4 animals each) received portal  injection with 1 x 
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Fig. 1. Functional test of transplanted lungs measured by arterial oxygen tension (Pao2). Arterial oxygen 
tension of grafted lung in FK (dotted lines) and PV + FK groups (solid lines) decreased as rejection 
developed. Therefore arterial oxygen tension in PV + FK group declined slower than that in FK group. 
106, 1 X 108, or 1 × 101° donor splenocytes imme- 
diately before lung transplantation. Control group 
dogs (6 animals) given no cells also received lung 
transplantation. As shown in Table I, portal venous 
inoculation with donor splenocytes alone did not 
affect he mean survival time of the grafted lung. 
Subsequently, effects of portal venous inoculation 
with donor splenocytes on the graft surviva! of FK 
506-treated recipients were examined. For this pur- 
pose, three groups of dogs (6 animals each) received 
(1) lung transplantation followed by FK 506 treat- 
ment for 14 days (FK group), (2) lung transplanta- 
tion preceded by portal venous inoculation with 1 × 
108 donor splenocytes (PV group), or (3) lung trans- 
plantation preceded by portal venous inoculation with 
donor splenocytes and followed by FK 506 treatment 
for 14 days (PV + FK group). The control group was 
the same as that in the first experiment. As shown in 
Table II, the mean graft survival time was 7.2 _+ 2.3 
days in the control group, 21.5 _+ 2.4 days in the FK 
group (p < 0.05 versus control group), 6.2 + 2.1 days 
in the PV group, and 38.0 _+ 12.8 days in the PV + FK 
group (p < 0.05 versus control group, FK group, and 
PV group). In the PV + FK group, the graft survival 
after termination ofFK 506 treatment was significantly 
longer (p < 0.05) than that in the FK group. The 
arterial oxygen tension (Fig. 1) of the grafted lung of 
individual recipients remained within the normal 
range for a longer period in the PV + FK group 
compared with findings in the FK group. Histologic 
examinations on day 21 revealed that, although mas- 
sive infiltration of mononuclear cells was observed in 
the FK group (Fig. 2, A), such cellular reaction was 
minimal in the PV + FK group (Fig. 2, B). Prolonged 
graft survival after termination of FK 506 treatment 
observed in the PV + FK group was not caused by the 
reduced catabolism of FK 506, because plasma FK 506 
concentrations were not significantly different between 
the FK group and the PV + FK group (Fig. 3). 
To determine whether the dose of 1 × 108 
splenocytes is optimal in causing the prolonged 
survival of the grafted lungs after termination of FK 
506 administration, two groups of dogs (4 animals 
each) were given lower (1 × 106) and higher (1 × 
10 l°) doses of donor splenocytes immediately before 
lung transplantation, and then these animals were 
treated with FK 506 for 14 days. Results in these 
groups were compared with those of the FK group 
and the PV + FK group in the second experiment. 
Although significant prolongation of the graft sur- 
vival was observed when 1 x 108 cells were inocu- 
lated, the higher or lower dose showed no effects or 
only marginal effects on the graft survival time 
(Table III). 
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Fig. 2. Histologic studies of transplanted lung of dog from PV + FK group and FK group (hematoxylin 
and eosin stain; original magnification × 85). A,On day 21 in FK group, marked infiltration of mononuclear 
cells indicating moderate rejection was observed in perivascular (arrow) and peribronchial (arrowhead) 
areas and also in alveolar walls (grade 3; moderate r jection). B, Biopsy specimen obtained from PV + FK 
group on same day, on the other hand, showed minimum mononuclear leukocytic infiltration in 
perivascular (arrow) and peribronchial (arrowhead) areas (grade 1; minimal rejection). 
Discussion 
The present results show that portal venous inoc- 
ulation with donor splenocytes alone did not cause 
prolonged graft survival in lung transplantation i  
dogs. However, survival time of the transplanted 
lung after termination of FK 506 administration was 
significantly prolonged by portal venous inoculation 
with donor splenocytes. Since Triger, Cynamon, and 
Wright 18 first reported a reduced immune response 
after injections of antigen into the portal system, 
portal venous inoculation with donor splenocytes 
has been proved as the effective way to induce 
allograft olerance in inbred rats. 6-12' 19, 2o Because 
the efficacy of portal venous inoculation with donor 
splenocytes was influenced by the strain combina- 
tions, 2! applicability of this effect to clinical organ 
transplantation should be examined in outbred com- 
binations of large animals. In this regard, prolonged 
survival of kidney allografts by portal venous inocula- 
tion with donor splenocytes in dogs was recently 
reported.12,13 It is well known that the immunogenicity 
to induce graft rejection reaction is extremely variable 
among tissues probably because of the variance in the 
expression of histocompatibility antigens and also in 
the content and the type of antigen-presenting cells. 22 
Therefore the effects of portal venous inoculation with 
donor splenocytes may also be variable depending on 
the grafted tissues. 
In small animals uch as rats, immunologic toler- 
ance to allograft was induced effectively by portal 
venous inoculation with donor splenocytes 1 week 
before organ transplantation. 6-11 In terms of clinical 
applicability, however, preoperative portal venous 
inoculation with donor splenocytes i  rather difficult 
and practically almost impossible. Therefore we 
performed portal venous inoculation with donor 
splenocytes at the time of lung transplantation. 
Similar to the method in our experiments, portal 
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Fig. 3. Plasma trough levels of FK 506. No significant difference was observed between FK (dotted line) 
and PV + FK groups (solid line) throughout period examined. 
Table III. Effects of portal venous inoculation with 
donor splenocytes on the graft survival in lung 
transplantation i dogs treated with FK 506 
No. of No. of Graft survival 
cel ls animals time (days) Mean +_ SD 
None 6 18, 20, 21, 22, 23, 25 21.5 2 2.4 
1.0 × 106 4 23, 23, 26, 26 24.5 + 1.7" 
1.0 × 108 6 26, 33, 34, 36, 36, 63 38.0 _+ 12.8t 
1.0 × 101° 4 17, 8, 19, 20 18.5 _+ 1.3" 
All animals were treated with FK 506 (0.1 mg/kg per day) for 14 days 
starting from day of lung transplantation. Data for the g oups given no 
cells and those given 1 × 08 cells appeared under FK group and PV + FK 
group, respectively, in Table II. SD, standard deviation. 
*Not significantly different from control group given no c lls. 
tp < 0.05 versus control group given no cells. 
venous inoculation with donor splenocytes was done 
at the time of renal transplantation i  dogs. 12'13 
Tanigawa and associates 23reported that immuno- 
logic tolerance induced by preoperative and periop- 
erative portal venous inoculation with donor spleno- 
cytes might be mediated by different mechanisms 
because mitomycin C treatment of donor spleno- 
cytes had different effects on graft survival. 
In the present s udy, despite the ineffectiveness of 
portal venous inoculation with donor splenocytes 
alone on the prolongation of graft survival time, rejec- 
tion of the grafted lungs after termination of FK 506 
administration was significantly delayed when the re- 
cipient was treated with perioperative portal venous 
inoculation with donor splenocytes. Because plasma 
FK 506 concentrations were not significantly different 
between the FK group and the PV + FK group, 
prolonged graft survival after termination of FK 506 
treatment observed in the PV + FK group was not a 
result of the reduced catabolism of the drug. FK 506 is 
thought o suppress helper T cell functions but not o 
inhibit suppressor T cell functions. 24 Moreover, FK 
506 was found to suppress presensitization-resistant 
cytotoxic T lymphocyte helpers (CD4 + CI?L - Th). 25 
The reason the combined therapy with donor spleno- 
cyte transfer and FK 506 treatment caused longer graft 
survival than FK 506 therapy alone is indeed uncer- 
tain. Further study on the reactivity of T cells from 
each group against donor antigens would elucidate 
underlying mechanisms. 
Dose response experiments revealed that pro- 
longed graft survival after termination of FK 506 
treatment was obtained only when 1 × 108 spleno- 
cytes were inoculated into the portal vein. Because 
the higher or lower dose did not affect the graft 
survival time after termination of FK 506 therapy, 
the effective dose of donor splenocytes seems to be 
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limited within a narrow range. Prolonged survival of 
kidney allografts in dogs by portal venous inocula- 
tion with donor splenocytes was also observed at the 
dose of 10 s to 109.12' 13 Cellular immune responses 
are induced at a higher or lower dose than the 
optimal dose for humoral immune responses. 26 
Therefore higher or lower doses of portal venous 
inoculation with donor splenocytes might induce 
cellular immune responses related to graft rejection. 
In conclusion, although portal venous inoculation 
with donor splenocytes alone did not cause prolon- 
gation of the survival time of transplanted lung in 
dogs, the graft survival time after termination ofFK 
506 treatment was significantly prolonged when the 
recipients were treated by portal venous inoculation 
with donor splenocytes atthe time of lung transplan- 
tation. Therefore ven if portal venous inoculation 
with donor splenocytes alone is ineffective in the 
induction of allograft olerance, this method may 
allow intermittent administration of FK 506 and 
thereby reduce the usage of the immunosuppressive 
agent. 
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